Revolutionizing Bleeding Treatment

Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage.
In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed.  The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to address any increase in demand, particularly mass casualty events, military conflicts or significant hemorrhage situations such as post-partum hemorrhage and traumatic injury. This means:

• Platelet rationing occurs across the system
• Nearly 400,000 platelet units a year expire before they can get to a patient in need
• Ten million Americans on anti-platelet or anticoagulant medications face greater risks when effective therapies aren’t available to clinicians, complicating surgery and trauma care.

‍Cellphire currently has two differentiated products in Phase 2 clinical studies, our freeze-dried platelet-derived hemostat "FPH" (Thrombosomes®), and our Cryopreserved Platelets "CPP".